Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
The DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.
Abstract
Notwithstanding the effectiveness of lowering LDL cholesterol, residual CVD risk remains in high-risk populations, including patients with diabetes, likely contributed to by non-LDL lipid abnormalities. In this Perspectives in Diabetes article, we emphasize that changing demographics and lifestyles over the past few decades have resulted in an epidemic of the “atherogenic dyslipidemia complex,” the main features of which include hypertriglyceridemia, low HDL cholesterol levels, qualitative changes in LDL particles, accumulation of remnant lipoproteins, and postprandial hyperlipidemia. We briefly review the underlying pathophysiology of this form of dyslipidemia, in particular its association with insulin resistance, obesity, and type 2 diabetes, and the marked atherogenicity of this condition. We explain the failure of existing classes of therapeutic agents such as fibrates, niacin, and cholesteryl ester transfer protein inhibitors that are known to modify components of the atherogenic dyslipidemia complex. Finally, we discuss targeted repurposing of existing therapies and review promising new therapeutic strategies to modify the atherogenic dyslipidemia complex. We postulate that targeting the central abnormality of the atherogenic dyslipidemia complex, the elevation of triglyceride-rich lipoprotein particles, represents a new frontier in CVD prevention and is likely to prove the most effective strategy in correcting most aspects of the atherogenic dyslipidemia complex, thereby preventing CVD events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin resistance with increased circulating FAs and decreased insulin signalling can also lead to increased chylomicron secretion.15”
From Clinical review on triglycerides (2020) · cites this paper as [15]
In the citing paper
“This milieu drives increased VLDL secretion, which is particularly enhanced when FA and insulin are in excess.15”
From Clinical review on triglycerides (2020) · cites this paper as [15]
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,378
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 1×
“Nonfasting TG level, which may reflect the atherogenic capacity of TRL remnants, is a stronger predictor of CVD events than fasting TG levels (19,20).”
BackgroundEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · cited 1×
“In the Dal-OUTCOMES study (87), dalcetrapib did not reduce the risk of recurrent cardiovascular events in patients who had experienced a recent acute coronary syndrome event, despite increased HDL-C levels.”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 2×
“Fibrates increase apoA-I and apoA-II transcription, enhance reverse cholesterol transport, and indirectly, through altered VLDL metabolism, increase HDL levels (66).”
BackgroundEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619 · cited 1×
“Nonfasting TG level, which may reflect the atherogenic capacity of TRL remnants, is a stronger predictor of CVD events than fasting TG levels (19,20).”
BackgroundBrown adipose tissue activity controls triglyceride clearance
Bartelt, A., Bruns, O. T., Reimer, R., Hohenberg, H., Ittrich, H., Peldschus, K., Kaul, M. G., Tromsdorf, U. I., Weller, H., Waurisch, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2297 · Cited by 1,608 · cited 1×
“Recently, it has been shown (128,129) in rodents that the activation of brown adipose tissue enhances fatty acid uptake by brown adipose tissue and the clearance of remnant cholesterol by liver, leading to the lowering of TG and cholesterol levels, translation of which into therapeutic means in humans awaits further s…”
BackgroundEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419 · cited 1×
“Atherogenic properties have been assigned to atherogenic dyslipidemia complex components, as has been reviewed for TRL levels (21), remnant lipoprotein levels (22), postprandial lipemia (23), nonfasting TG levels (24), sdLDL particles (25), and the antiatherosclerotic properties of HDL (26).”
BackgroundAtherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411 · cited 1×
“Such lipid and lipoprotein abnormalities have been referred to as the “atherogenic lipoprotein phenotype” (9) or “atherogenic dyslipidemia” (10), which imply a causal relationship between the phenotype and atherosclerosis.”
BackgroundSarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 1×
“Likewise, TG levels were strongly and independently associated with coronary heart disease risk in a meta-analysis of 29 prospective studies (18).”
BackgroundInsulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Lewis, G. F., Carpentier, A., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,333 · cited 3×
“Also, as discussed below, the features of this cluster of lipid/lipoprotein abnormalities intertwine in their metabolism converging on triglyceride (TG)-rich lipoproteins (TRLs).”
BackgroundInfluentialSelf-citationManninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329 · cited 2×
“More recent trials, including FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) (fenofibrate in T2D patients) (69,70), BIP (Bezafibrate Infarction Prevention) (bezafibrate) (71), HHS (Helsinki Heart Study) (gemfibrozil) (17), ACCORD-Lipid (fenofibrate in statin-treated T2D patients) (72), and VAHIT (Vete…”
BackgroundPrevalence of the metabolic syndrome in the United States, 2003-2012
Aguilar, M., Bhuket, T., Torres, S., Liu, B., & Wong, R. J. (2015) · JAMA · doi:10.1001/jama.2015.4260 · Cited by 1,267 · cited 1×
“(13), the prevalence of the atherogenic dyslipidemia complex is expected to be alarmingly high.”
BackgroundA Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
Goldstein, J. L., & Brown, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.01.036 · Cited by 1,233 · cited 1×
“Epidemiological, genetic, and animal studies and randomized, controlled clinical trials support a central role for LDL cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease (CVD) events (1).”
BackgroundChapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115 · cited 1×
“Finally, it has been suggested that the cholesterol rather than the TG content of remnant lipoproteins, which can be estimated from nonfasting lipids, drives the atherogenicity of these particles (33).”
BackgroundNew Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport
Lewis, G. F., & Rader, D. J. (2005) · Circulation Research · doi:10.1161/01.res.0000170946.56981.5c · Cited by 1,093
Self-citationLoss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927 · cited 2×
“In a meta-analysis (75) of 18 prospective randomized controlled trials with fibrates, CVD benefits in the whole study population were very modest.”
Robins, S. J., Collins, D., Wittes, J. T., Papademetriou, V., Deedwania, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., Wexler, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 921
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919 · cited 1×
“Carriers of rare loss-offunction mutations in the APOC3 gene have low TG levels and reduced CVD risk (95,96).”
BackgroundThe effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · cited 1×
“For example, an FGF21 analog, originally developed as a glucose-lowering agent for the treatment of T2D, has demonstrated greater lipid-modifying effects in obese subjects with T2D, including lowering TG, total cholesterol, and LDL-C levels, and increasing HDL-C levels (127).”
BackgroundCommon variants associated with plasma triglycerides and risk for coronary artery disease
Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2795 · Cited by 862 · cited 1×
“Indeed, huge sample sizes and complicated statistical genetic models cannot fully dissociate such interrelationships (52).”
Dysfunctional HDL and atherosclerotic cardiovascular disease
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.124 · Cited by 822 · cited 2×
“Atherogenic properties have been assigned to atherogenic dyslipidemia complex components, as has been reviewed for TRL levels (21), remnant lipoprotein levels (22), postprandial lipemia (23), nonfasting TG levels (24), sdLDL particles (25), and the antiatherosclerotic properties of HDL (26).”
BackgroundBoekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795 · cited 2×
“Consequently, non-HDL-C is strongly associated with coronary heart disease risk (29,31).”
BackgroundNinomiya, J. K., L’Italien, G., Criqui, M. H., Whyte, J. L., Gamst, A., & Chen, R. S. (2004) · Circulation · doi:10.1161/01.cir.0000108926.04022.0c · Cited by 793 · cited 1×
“For instance, high TG levels and low HDL-C levels in the NHANES (National Health and Nutrition Examination Survey) III study (14) were each strongly and independently correlated with major CVD events.”
BackgroundAnderson, T. J., Grégoire, J., Hegele, R. A., Couture, P., Mancini, G. B. J., McPherson, R., Francis, G. A., Poirier, P., Lau, D. C., Grover, S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.11.032 · Cited by 770
Self-citationExome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754 · cited 3×
“Loss-of-function mutations in ANGPTL3 also cause hypolipoproteinemia with low–apoB-containing lipoproteins and HDL-C (63), and loss-of-function mutations in other angiopoietin-like protein (ANGPTL) family members also are associated with low plasma TG levels (64,65).”
BackgroundSafety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744
Self-citationExtended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M., Weissman, N. J., & Turco, M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 644 · cited 1×
“In the ARBITER 6-HALTS (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) trial (82), extended-release niacin induced the regression of carotid intima-media thickness in patients receiving statin.”
BackgroundHegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Self-citationHypertriglyceridemia: its etiology, effects and treatment
Yuan, G., Al-Shali, K. Z., & Hegele, R. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060963 · Cited by 624 · cited 2×
“, insulin resistance, metabolic syndrome, untreated or poorly controlled diabetes), pregnancy, and certain medications (54).”
BackgroundSelf-citationScott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Cardiovascular effects of marine omega-3 fatty acids
Saravanan, P., Davidson, N. C., Schmidt, E. B., & Calder, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60445-x · Cited by 511 · cited 1×
“Their mechanisms of action are multifaceted, including an antiarrhythmic effect, plasma TG reduction, blood pressure lowering, a decrease in platelet aggregation, improvement of vascular reactivity, and an anti-inflammation effect (125).”
BackgroundRomeo, S., Pennacchio, L. A., Fu, Y., Boerwinkle, E., Tybjaerg-Hansen, A., Hobbs, H. H., & Cohen, J. C. (2007) · Nature Genetics · doi:10.1038/ng1984 · Cited by 511
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497 · cited 1×
“The inhibition of ANGPTL4 with antibody reduced serum TG levels in mice and monkeys (105).”
BackgroundCoding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491 · cited 2×
“Besides modulating the clearance of TRL by LPL, apoC3 may be involved in TRL production, as suggested by the findings that apoC3 antisense reduced TG levels and TRL particle numbers in patients with null LPL mutation (58).”
BackgroundBARTER, P. J., BALLANTYNE, C. M., CARMENA, R., CABEZAS, M. C., CHAPMAN, M. J., COUTURE, P., DE GRAAF, J., DURRINGTON, P. N., FAERGEMAN, O., FROHLICH, J., et al. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01616.x · Cited by 464 · cited 1×
“total apoB (30) levels are often increased along with the atherogenic dyslipidemia complex.”
BackgroundFruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Plasma lipoproteins: genetic influences and clinical implications
Hegele, R. A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2481 · Cited by 462 · cited 1×
“A few rare and many common genetic variants in the LPL gene have been identified and linked to the lipid abnormalities that characterize the atherogenic dyslipidemia complex (54,55).”
BackgroundSelf-citationExcess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia
Johansen, C. T., Wang, J., Lanktree, M. B., Cao, H., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., et al. (2010) · Nature Genetics · doi:10.1038/ng.628 · Cited by 437 · cited 1×
“Variants in GCKR encoding glucokinase regulatory protein are associated with HTG, possibly through affecting TG biosynthesis (59).”
BackgroundSelf-citationBrown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development
Berbée, J. F. P., Boon, M. R., Khedoe, P. P. S. J., Bartelt, A., Schlein, C., Worthmann, A., Kooijman, S., Hoeke, G., Mol, I. M., John, C., et al. (2015) · Nature Communications · doi:10.1038/ncomms7356 · Cited by 435 · cited 1×
“Recently, it has been shown (128,129) in rodents that the activation of brown adipose tissue enhances fatty acid uptake by brown adipose tissue and the clearance of remnant cholesterol by liver, leading to the lowering of TG and cholesterol levels, translation of which into therapeutic means in humans awaits further s…”
BackgroundIncreased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance
Choi, S. H., & Ginsberg, H. N. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.04.007 · Cited by 418 · cited 1×
“Diminished post-translational apoB-100 degradation in hepatocytes with increased biogenesis, stability, and secretion of nascent VLDL particles has been demonstrated in insulin resistance, resulting in increased production of VLDL by the liver (42).”
BackgroundBallantyne, C. M., Olsson, A. G., Cook, T. J., Mercuri, M. F., Pedersen, T. R., & Kjekshus, J. (2001) · Circulation · doi:10.1161/hc5001.100624 · Cited by 416 · cited 1×
“The presence of high TG and low HDL-C levels, concurrent with high LDL-C levels, increased CVD risks in the Scandinavian Simvastatin Survival Study (16) and in the Helsinki Heart Study (17).”
BackgroundAtypical angiopoietin-like protein that regulates ANGPTL3
Quagliarini, F., Wang, Y., Kozlitina, J., Grishin, N. V., Hyde, R., Boerwinkle, E., Valenzuela, D. M., Murphy, A. J., Cohen, J. C., & Hobbs, H. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217552109 · Cited by 409 · cited 1×
“Loss-of-function mutations in ANGPTL3 also cause hypolipoproteinemia with low–apoB-containing lipoproteins and HDL-C (63), and loss-of-function mutations in other angiopoietin-like protein (ANGPTL) family members also are associated with low plasma TG levels (64,65).”
BackgroundGaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404 · cited 1×
“with LPL deficiency and chylomicronemia with severe HTG, ongoing evaluation of LPL gene therapy shows some promise (94).”
BackgroundDynamics of human adipose lipid turnover in health and metabolic disease
Arner, P., Bernard, S., Salehpour, M., Possnert, G., Liebl, J., Steier, P., Buchholz, B. A., Eriksson, M., Arner, E., Hauner, H., et al. (2011) · Nature · doi:10.1038/nature10426 · Cited by 400
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377 · cited 1×
“Antisense inhibition of apoC3 in preclinical models and in a phase I clinical trial of healthy subjects decreased plasma concentrations of apoC3 and TG (97).”
BackgroundMechanisms for the Hypotriglyceridemic Effect of Marine Omega-3 Fatty Acids
Davidson, M. H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.024 · Cited by 374 · cited 1×
“It has been postulated that the hypolipidemic effect of n-3 fatty acids may be due to reduced hepatic lipogenesis, increased fatty acid oxidation, and suppressed VLDL secretion, although the exact mechanisms remain to be elucidated (126).”
BackgroundRobinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368 · cited 1×
“Consequently, non-HDL-C is strongly associated with coronary heart disease risk (29,31).”
BackgroundChylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356 · cited 1×
“Although rare monogenic forms of severe HTG manifesting as chylomicronemia exist (50), the majority of cases of HTG are typically mild to moderate and have a polygenic basis.”
BackgroundSelf-citationKrishna, R., Anderson, M. S., Bergman, A. J., Jin, B., Fallon, M., Cote, J., Rosko, K., Chavez-Eng, C., Lutz, R., Bloomfield, D. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61813-3 · Cited by 277 · cited 1×
“For instance, anacetrapib increases levels of HDL-C and decreases levels of both LDL-C and apoB-100 (89,90), and, when added to statin treatment, results in further reductions in LDL-C (91,92).”
BackgroundBruckert, E., Labreuche, J., & Amarenco, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.023 · Cited by 273 · cited 2×
“Niacin Earlier studies, dating back to the 1970s, showed that niacin (nicotinic acid) reduced CVD (78).”
BackgroundGenome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis
Wagschal, A., Najafi-Shoushtari, S. H., Wang, L., Goedeke, L., Sinha, S., deLemos, A. S., Black, J. C., Ramírez, C. M., Li, Y., Tewhey, R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3980 · Cited by 254 · cited 1×
“, microRNAs) may regulate the expression of proteins involved in lipoprotein-cholesterol and TG metabolism (56), which adds to the expanded genetic contribution to dyslipidemia.”
BackgroundCombination lipid therapy in type 2 diabetes
(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245
Bloomfield, D., Carlson, G. L., Sapre, A., Tribble, D., McKenney, J. M., Littlejohn, T. W., Sisk, C. M., Mitchel, Y., & Pasternak, R. C. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.09.022 · Cited by 243 · cited 1×
“For instance, anacetrapib increases levels of HDL-C and decreases levels of both LDL-C and apoB-100 (89,90), and, when added to statin treatment, results in further reductions in LDL-C (91,92).”
BackgroundPinkosky, S. L., Filippov, S., Srivastava, R. A. K., Hanselman, J. C., Bradshaw, C. D., Hurley, T. R., Cramer, C. T., Spahr, M. A., Brant, A. F., Houghton, J. L., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m030528 · Cited by 239
Shi, Y., & Cheng, D. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90949.2008 · Cited by 232 · cited 1×
“Diacylglycerol Acyltransferase and Monoacylglycerol Acyltransferase Inhibition Pharmacological inhibition of enzymes involved in TG biosynthesis, namely, diacylglycerol acyltransferase (DGAT) and monoacylglycerol acyltransferase (MGAT), has shown promise for the treatment of obesity, diabetes, and dyslipidemia in anim…”
BackgroundTriacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein
Packard, C. J. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311066 · Cited by 225 · cited 1×
“In HTG, there is increased secretion of TG-enriched, larger VLDL particles, which are precursors of sdLDL, and increased delipidation of larger buoyant LDL to form sdLDL; furthermore, the liver directly secretes more LDL particles of smaller size in HTG (25,36,37).”
BackgroundYaghootkar, H., Scott, R. A., White, C. C., Zhang, W., Speliotes, E., Munroe, P. B., Ehret, G. B., Bis, J. C., Fox, C. S., Walker, M., et al. (2014) · Diabetes · doi:10.2337/db14-0318 · Cited by 220
Gusarova, V., Alexa, C. A., Wang, Y., Rafique, A., Kim, J. H., Buckler, D., Mintah, I. J., Shihanian, L. M., Cohen, J. C., Hobbs, H. H., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054890 · Cited by 210 · cited 1×
“The blockade of ANGPTL3 with antibody reduced plasma lipids, including TG, non-HDL-C, and HDL-C in mice and monkeys (99), which is likely associated with reduced VLDL TG production and increased clearance of apoB-containing lipoproteins (100).”
BackgroundRegulation of lipoprotein lipase by Angptl4
Dijk, W., & Kersten, S. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.005 · Cited by 198 · cited 1×
“ANGPTL4 inhibits LPL and is a major regulator of LPL activity during fasting and exercise (101).”
BackgroundNew insights into the regulation of chylomicron production
Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034338 · Cited by 194 · cited 1×
“Although there are some differences in the regulation of VLDL and chylomicron particle production, similar mechanisms are also likely to be involved in enhancing chylomicron production in the intestine (43,44).”
BackgroundSelf-citationFruchart, J.-C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-82 · Cited by 189 · cited 1×
“More potent and selective PPARa agonists and PPARa/g dual-receptor agonists are being developed (77).”
BackgroundInactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
Wang, Y., Gusarova, V., Banfi, S., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054882 · Cited by 189 · cited 1×
“The blockade of ANGPTL3 with antibody reduced plasma lipids, including TG, non-HDL-C, and HDL-C in mice and monkeys (99), which is likely associated with reduced VLDL TG production and increased clearance of apoB-containing lipoproteins (100).”
BackgroundDuez, H., Lamarche, B., Uffelman, K. D., Valero, R., Cohn, J. S., & Lewis, G. F. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000222015.76038.14 · Cited by 187
Self-citationPostprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182 · cited 1×
“Atherogenic properties have been assigned to atherogenic dyslipidemia complex components, as has been reviewed for TRL levels (21), remnant lipoprotein levels (22), postprandial lipemia (23), nonfasting TG levels (24), sdLDL particles (25), and the antiatherosclerotic properties of HDL (26).”
BackgroundYen, C.-L. E., Cheong, M.-L., Grueter, C., Zhou, P., Moriwaki, J., Wong, J. S., Hubbard, B., Marmor, S., & Farese, R. V. (2009) · Nature Medicine · doi:10.1038/nm.1937 · Cited by 180 · cited 1×
“MGAT2 is exclusively expressed in the intestine, where the MGAT pathway accounts for ;75% of TG synthesis (109), and MGAT plays an important role in dietary lipid absorption.”
BackgroundBallantyne, C. M., Davidson, M. H., MacDougall, D. E., Bays, H. E., DiCarlo, L. A., Rosenberg, N. L., Margulies, J., & Newton, R. S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.050 · Cited by 175
Gutierrez, M. J., Rosenberg, N. L., MacDougall, D. E., Hanselman, J. C., Margulies, J. R., Strange, P., Milad, M. A., McBride, S. J., & Newton, R. S. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.302677 · Cited by 170 · cited 10×
“It is well established that insulin resistance underlies many features of metabolic defects in metabolic syndrome and T2D and that TRL production is known to be increased in insulin resistance.”
BackgroundInfluentialHypobetalipoproteinemia and abetalipoproteinemia
Welty, F. K. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000072 · Cited by 167 · cited 1×
“Loss-of-function mutations in APOB impair apoB trafficking and secretion or enhance its catabolism, causing hypobetalipoproteinemia with low plasma TG, apoB, and LDL-C levels (61) and reduced risk of atherosclerotic CVD (62).”
BackgroundXiao, C., Bandsma, R. H. J., Dash, S., Szeto, L., & Lewis, G. F. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.246207 · Cited by 164 · cited 1×
“Among those, the incretin-based antidiabetic drugs exenatide (a glucagon-like peptide-1 receptor agonist) and sitagliptin (a dipeptidyl peptidase-4 inhibitor) suppress intestinal lipoprotein production in the short term in humans (119,120).”
BackgroundSelf-citationEffect of Weight Loss with Reduction of Intra-Abdominal Fat on Lipid Metabolism in Older Men
Purnell, J. Q. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.3.977 · Cited by 161 · cited 1×
“Weight loss improves many components of the atherogenic dyslipidemia complex (130,131).”
BackgroundUse of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance
Thompson, P. D., Rubino, J., Janik, M. J., MacDougall, D. E., McBride, S. J., Margulies, J. R., & Newton, R. S. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.03.003 · Cited by 159 · cited 1×
“In statin-intolerant patients with hypercholesterolemia, ETC-1002 decreased non-HDL-C, total cholesterol, and apoB levels without significantly affecting TG and HDL levels (118).”
BackgroundIntestinal triacylglycerol synthesis in fat absorption and systemic energy metabolism
Yen, C.-L. E., Nelson, D. W., & Yen, M.-I. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r052902 · Cited by 156 · cited 1×
“DGAT1 is abundantly expressed in the small intestine (110).”
BackgroundHypertriglyceridemia in the genomic era: a new paradigm
Lewis, G. F., Xiao, C., & Hegele, R. A. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1062 · Cited by 152 · cited 2×
“the cumulative effects of the polygenic susceptibility and multiple environmental burdens may each increase the risks for the development of HTG (34).”
BackgroundSelf-citationThe composition and metabolism of large and small LDL
Diffenderfer, M. R., & Schaefer, E. J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000067 · Cited by 151 · cited 2×
“Atherogenic properties have been assigned to atherogenic dyslipidemia complex components, as has been reviewed for TRL levels (21), remnant lipoprotein levels (22), postprandial lipemia (23), nonfasting TG levels (24), sdLDL particles (25), and the antiatherosclerotic properties of HDL (26).”
BackgroundLamon-Fava, S., Diffenderfer, M. R., Barrett, P. H. R., Buchsbaum, A., Nyaku, M., Horvath, K. V., Asztalos, B. F., Otokozawa, S., Ai, M., Matthan, N. R., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.164541 · Cited by 149 · cited 1×
“Kinetic studies have indicated that extended-release niacin decreases the production of apo(a) and apoB-100–containing lipoproteins (79), increases the production of apoA-I, enhances the clearance of TRL apoB100 and apoB-48 (80), and reduces the fractional catabolic rate of apoA-I (81).”
BackgroundSantos, R. D., Duell, P. B., East, C., Guyton, J. R., Moriarty, P. M., Chin, W., & Mittleman, R. S. (2015) · European Heart Journal · doi:10.1093/eurheartj/eht549 · Cited by 143 · cited 2×
“Both mipomersen and the oral microsomal triglyceride transfer protein inhibitor (lomitapide) can also cause hepatotoxicity (106,107).”
BackgroundFibrates for secondary prevention of cardiovascular disease and stroke
Wang, D., Liu, B., Tao, W., Hao, Z., & Liu, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009580.pub2 · Cited by 142 · cited 1×
“A recently published Cochrane Database systematic review (76) of 13 fibrate randomized controlled trials showed evidence for a significant 12% protective effect of fibrates compared with placebo for CVD but no reduction in all-cause mortality or death from vascular disease.”
BackgroundLipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis
Schwartz, E. A., & Reaven, P. D. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.021 · Cited by 130 · cited 1×
“Atherogenic properties have been assigned to atherogenic dyslipidemia complex components, as has been reviewed for TRL levels (21), remnant lipoprotein levels (22), postprandial lipemia (23), nonfasting TG levels (24), sdLDL particles (25), and the antiatherosclerotic properties of HDL (26).”
BackgroundHogue, J.-C., Lamarche, B., Tremblay, A. J., Bergeron, J., Gagné, C., & Couture, P. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m600548-jlr200 · Cited by 129 · cited 10×
“It is well established that insulin resistance underlies many features of metabolic defects in metabolic syndrome and T2D and that TRL production is known to be increased in insulin resistance.”
BackgroundInfluentialGut-liver interaction in triglyceride-rich lipoprotein metabolism
Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 127
Self-citationThe effect of PPAR-α agonism on apolipoprotein metabolism in humans
Shah, A., Rader, D. J., & Millar, J. S. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.11.010 · Cited by 124 · cited 1×
“Kinetic studies (67) have indicated that fibrates lower VLDL apoB-100 levels through enhanced clearance and decreased production.”
BackgroundDietary and Genetic Probes of Atherogenic Dyslipidemia
Krauss, R. M. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000186365.73973.f0 · Cited by 124 · cited 1×
“In HTG, there is increased secretion of TG-enriched, larger VLDL particles, which are precursors of sdLDL, and increased delipidation of larger buoyant LDL to form sdLDL; furthermore, the liver directly secretes more LDL particles of smaller size in HTG (25,36,37).”
BackgroundBasel‐Vanagaite, L., Zevit, N., Har‐Zahav, A., Guo, L., Parathath, S., Pasmanik‐Chor, M., McIntyre, A. D., Wang, J., Albin‐Kaplanski, A., Hartman, C., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.11.028 · Cited by 113
Self-citationHepatic and Cardiovascular Consequences of Familial Hypobetalipoproteinemia
Sankatsing, R. R., Fouchier, S. W., de Haan, S., Hutten, B. A., de Groot, E., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000176191.64314.07 · Cited by 106 · cited 1×
“Loss-of-function mutations in APOB impair apoB trafficking and secretion or enhance its catabolism, causing hypobetalipoproteinemia with low plasma TG, apoB, and LDL-C levels (61) and reduced risk of atherosclerotic CVD (62).”
BackgroundDenison, H., Nilsson, C., Löfgren, L., Himmelmann, A., Mårtensson, G., Knutsson, M., AL‐Shurbaji, A., Tornqvist, H., & Eriksson, J. W. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12221 · Cited by 104 · cited 1×
“DGAT1 inhibition reduced postprandial TG plasma excursion in humans; however, this was accompanied by gastrointestinal side effects (111).”
BackgroundWilliams, P. T., Zhao, X.-Q., Marcovina, S. M., Otvos, J. D., Brown, B. G., & Krauss, R. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.01.034 · Cited by 94 · cited 1×
“Specialized analyses, such as gradient gel electrophoresis, vertical auto profile, nuclear magnetic resonance, or ion mobility, may yield information on cholesterol levels in lipoprotein subfractions to gain deeper insight into atherosclerotic risk (27).”
BackgroundRegulation of chylomicron production in humans
Xiao, C., & Lewis, G. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.019 · Cited by 91 · cited 1×
“Although there are some differences in the regulation of VLDL and chylomicron particle production, similar mechanisms are also likely to be involved in enhancing chylomicron production in the intestine (43,44).”
BackgroundSelf-citationGriffith, D. A., Kung, D. W., Esler, W. P., Amor, P. A., Bagley, S. W., Beysen, C., Carvajal-Gonzalez, S., Doran, S. D., Limberakis, C., Mathiowetz, A. M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5016022 · Cited by 90 · cited 1×
“A phase I clinical study (114) of one such compound demonstrated the inhibition of de novo lipogenesis and increased wholebody fatty acid oxidation.”
BackgroundAnacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
Millar, J. S., Reyes-Soffer, G., Jumes, P., Dunbar, R. L., deGoma, E. M., Baer, A. L., Karmally, W., Donovan, D. S., Rafeek, H., Pollan, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80025 · Cited by 89 · cited 1×
“Anacetrapib treatment also increases the LDL TG/cholesterol ratio and LDL size and increases LDL-apoB-100 clearance (93).”
BackgroundXiao, C., Dash, S., Morgantini, C., Patterson, B. W., & Lewis, G. F. (2014) · Diabetes · doi:10.2337/db13-1654 · Cited by 72 · cited 1×
“Among those, the incretin-based antidiabetic drugs exenatide (a glucagon-like peptide-1 receptor agonist) and sitagliptin (a dipeptidyl peptidase-4 inhibitor) suppress intestinal lipoprotein production in the short term in humans (119,120).”
BackgroundSelf-citationAcetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome.
Harwood, H. J. (2004) · PubMed · Cited by 62
Shojaee-Moradie, F., Ma, Y., Lou, S., Hovorka, R., & Umpleby, A. M. (2013) · Diabetes · doi:10.2337/db13-0935 · Cited by 60 · cited 1×
“Thus, the production of intestinally derived TRL apoB-48 is also increased in insulin resistance (45), obesity (46), and T2D (47,48), and chylomicron TG secretion is increased in metabolic syndrome (49).”
BackgroundXiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 60
Self-citationA 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients
Lemieux, I., Laperrière, L., Džavík, V., Tremblay, G., Bourgeois, J., & Després, J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00711-0 · Cited by 58 · cited 1×
“Fibrates are less effective at lowering LDL-C or apoB concentrations but may shift LDL particles from small to large size (68).”
BackgroundRomeo, S., Yin, W., Kozlitina, J., Pennacchio, L. A., Boerwinkle, E., Hobbs, H. H., & Cohen, J. C. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37118 · Cited by 58 · cited 1×
“Loss-of-function mutations in ANGPTL3 also cause hypolipoproteinemia with low–apoB-containing lipoproteins and HDL-C (63), and loss-of-function mutations in other angiopoietin-like protein (ANGPTL) family members also are associated with low plasma TG levels (64,65).”
BackgroundOoi, E. M., Watts, G. F., Chan, D. C., Pang, J., Tenneti, V. S., Hamilton, S. J., McCormick, S. P., Marcovina, S. M., & Barrett, P. H. R. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306136 · Cited by 54 · cited 1×
“Kinetic studies have indicated that extended-release niacin decreases the production of apo(a) and apoB-100–containing lipoproteins (79), increases the production of apoA-I, enhances the clearance of TRL apoB100 and apoB-48 (80), and reduces the fractional catabolic rate of apoA-I (81).”
BackgroundAbsence of Acute Inhibitory Effect of Insulin on Chylomicron Production in Type 2 Diabetes
Nogueira, J.-P., Maraninchi, M., Béliard, S., Padilla, N., Duvillard, L., Mancini, J., Nicolay, A., Xiao, C., Vialettes, B., Lewis, G. F., et al. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.242073 · Cited by 52 · cited 10×
“It is well established that insulin resistance underlies many features of metabolic defects in metabolic syndrome and T2D and that TRL production is known to be increased in insulin resistance.”
BackgroundInfluentialSelf-citationMeyers, C. D., Amer, A., Majumdar, T., & Chen, J. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.509 · Cited by 47 · cited 1×
“Other DGAT1 inhibitor compounds are being developed, with the hope of satisfactory efficacy, safety, and tolerability (112).”
BackgroundPadilla, N., Maraninchi, M., Béliard, S., Berthet, B., Nogueira, J.-P., Wolff, E., Nicolay, A., Bégu, A., Dubois, N., Grangeot, R., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303849 · Cited by 43 · cited 1×
“Bariatric surgery, the most effective intervention in inducing sustained weight loss, also reduces TRL production (132,133).”
BackgroundSelf-citationExploring the value of apoB48 as a marker for atherosclerosis in clinical practice
Alipour, A., Valdivielso, P., Elte, J. W. F., Janssen, H. W., Rioja, J., van der Meulen, N., van Mechelen, R., Njo, T. L., González‐Santos, P., Rietveld, A. P., et al. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02635.x · Cited by 40 · cited 1×
“ApoB-48, the apolipoprotein present in chylomicrons and remnants, may serve as a surrogate marker of atherosclerosis in patients at risk (28).”
BackgroundWong, A. T. Y., Chan, D. C., Pang, J., Watts, G. F., & Barrett, P. H. R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2477 · Cited by 38 · cited 1×
“Thus, the production of intestinally derived TRL apoB-48 is also increased in insulin resistance (45), obesity (46), and T2D (47,48), and chylomicron TG secretion is increased in metabolic syndrome (49).”
BackgroundStudy, T. L. A., Smart-Halajko, M. C., Kelley-Hedgepeth, A., Montefusco, M. C., Cooper, J. A., Kopin, A., McCaffery, J. M., Balasubramanyam, A., Pownall, H. J., Nathan, D. M., et al. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-89 · Cited by 37
Pang, J., Chan, D. C., Hamilton, S. J., Tenneti, V. S., Watts, G. F., & Barrett, P. H. R. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302019 · Cited by 35
Intensive Lipid Lowering with Atorvastatin in Coronary Disease
Auer, J., Lamm, G., & Eber, B. (2005) · New England Journal of Medicine · doi:10.1056/nejm200507073530117 · Cited by 34 · cited 1×
“” Intensifying statin therapy may provide additional benefits (4,5); this approach, however, has limited potential, owing to tolerability, side effects, and finite efficacy.”
BackgroundBrinton, E. A., Kher, U. A., Shah, S., Cannon, C. P., Davidson, M. H., Gotto, A. M., Ashraf, T. B., Sisk, C. M., Dansky, H. M., Mitchel, Y., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.10.005 · Cited by 28 · cited 1×
“For instance, anacetrapib increases levels of HDL-C and decreases levels of both LDL-C and apoB-100 (89,90), and, when added to statin treatment, results in further reductions in LDL-C (91,92).”
BackgroundHeymans, S. R. B., Luttun, A., Collen, D., & Carmeliet, P. (2000) · Circulation · Cited by 20
Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism
Dash, S., Xiao, C., & Lewis, G. F. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000252 · Cited by 14 · cited 1×
“Bariatric surgery, the most effective intervention in inducing sustained weight loss, also reduces TRL production (132,133).”
BackgroundSelf-citationSiri‐Tarino, P. W., Woods, A. C., Bray, G. A., & Krauss, R. M. (2010) · Obesity · doi:10.1038/oby.2010.142 · Cited by 11 · cited 1×
“Weight loss improves many components of the atherogenic dyslipidemia complex (130,131).”
BackgroundMechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes
Watts, G. F., & Chan, D. C. (2010) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2010.04.044 · Cited by 10
Duivenvoorden, R., & Fayad, Z. A. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835916b3 · Cited by 10 · cited 1×
“The adverse effects of torcetrapib may have been due to off-target effects (86).”
BackgroundCholesteryl ester transfer protein: ace of spades, queen of hearts, or the joker?
Miller, N. E. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00145 · Cited by 7
Cited by
Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus
Palomer, X., Pizarro-Delgado, J., Barroso, E., & Vázquez-Carrera, M. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.11.009 · Cited by 548
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
“15 Furthermore, hyperglycaemia stimulates, while glucagon-like peptide 1 inhibits chylomicron secretion.”
BackgroundSelf-citationA Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 469
“CHL also largely overlaps with the so-called “atherogenic dyslipidemia complex,” which is associated with obesity, insulin resistance, and type 2 diabetes (227); this association reinforces the important role of secondary factors underlying this phenotype.”
BackgroundSelf-citationDuran, E. K., Aday, A. W., Cook, N. R., Buring, J. E., Ridker, P. M., & Pradhan, A. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.059 · Cited by 334
PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253
“The role of fibrates in the clinical management of disorders characterized by elevated TGs is now well established [60].”
Background
Metadata
- Authors
- Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F.
- Affiliations
- University of Toronto (CA)
- Western University (CA)
- Corresponding author
- Lewis, Gary F.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2016-06-13
- Volume
- 65
- Issue
- 7
- Pages
- 1767-1778
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2472281584
- Cited by
- 212
- References
- 137
- Citations by year
- 2026: 6 · 2025: 21 · 2024: 20 · 2023: 20 · 2022: 34 · 2021: 35 · 2020: 23 · 2019: 25 · 2018: 13 · 2017: 12 · 2016: 2
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP‑79533), MOP13430, MOP-43839)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- residual cardiovascular risk, hypertriglyceridemia, low HDL cholesterol, remnant lipoproteins, postprandial lipemia, triglyceride-rich lipoproteins, insulin resistance, type 2 diabetes, obesity, fibrates, nicotinic acid, cholesteryl ester transfer protein inhibitors, drug repurposing, cardiovascular disease prevention
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Humans, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.